PharmX Technologies Limited (ASX:PHX)
Australia · Delayed Price · Currency is AUD 0.1150
0.00 (0.00%)
Jun 17, 2026, 4:10 PM AEST
PharmX Technologies Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 7.49 | 7.32 | 6.49 | 6.13 | 5.39 | 11.88 |
Other Revenue | 0.16 | 0.21 | 1.61 | - | - | - |
| 7.65 | 7.53 | 8.09 | 6.13 | 5.39 | 11.88 | |
Revenue Growth (YoY) | -11.41% | -6.97% | 32.10% | 13.78% | -54.65% | 11.58% |
Cost of Revenue | 5.91 | 5.4 | 4.13 | 4.12 | 3.25 | 8.5 |
Gross Profit | 1.73 | 2.13 | 3.96 | 2.01 | 2.14 | 3.38 |
Selling, General & Admin | 1.07 | 0.84 | 2.64 | 1.7 | 1.15 | 0.98 |
Research & Development | -0.4 | -0.32 | -0.14 | -0.09 | -0.1 | -0.62 |
Other Operating Expenses | - | - | - | - | 0.09 | 0.02 |
Operating Expenses | 2.44 | 2.02 | 3.72 | 2.67 | 2.01 | 2.16 |
Operating Income | -0.71 | 0.11 | 0.24 | -0.67 | 0.13 | 1.22 |
Interest Expense | -0.03 | -0.03 | -0.04 | -0.05 | -0.01 | -0.13 |
EBT Excluding Unusual Items | -0.74 | 0.08 | 0.2 | -0.72 | 0.12 | 1.09 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 1.73 |
Other Unusual Items | - | - | - | - | - | -1.47 |
Pretax Income | -0.74 | 0.08 | 0.2 | -0.72 | 0.12 | 1.35 |
Income Tax Expense | 0.19 | 0.34 | 0.11 | 0.16 | 0.25 | 0.27 |
Earnings From Continuing Operations | -0.93 | -0.26 | 0.1 | -0.88 | -0.13 | 1.08 |
Earnings From Discontinued Operations | - | - | -1.86 | -0.17 | 0.38 | 0.01 |
Net Income | -0.93 | -0.26 | -1.77 | -1.05 | 0.25 | 1.09 |
Net Income to Common | -0.93 | -0.26 | -1.77 | -1.05 | 0.25 | 1.09 |
Net Income Growth | - | - | - | - | -76.90% | 519.89% |
Shares Outstanding (Basic) | 599 | 599 | 598 | 597 | 597 | 543 |
Shares Outstanding (Diluted) | 599 | 599 | 598 | 597 | 601 | 547 |
Shares Change (YoY) | -1.38% | 0.06% | 0.17% | -0.56% | 9.81% | 57.55% |
EPS (Basic) | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
EPS (Diluted) | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
EPS Growth | - | - | - | - | -78.89% | 300.60% |
Free Cash Flow | 0.98 | -8.16 | 3.19 | 10.86 | 3.19 | 2.86 |
Free Cash Flow Per Share | 0.00 | -0.01 | 0.01 | 0.02 | 0.01 | 0.01 |
Gross Margin | 22.66% | 28.23% | 48.98% | 32.72% | 39.74% | 28.44% |
Operating Margin | -9.30% | 1.46% | 3.02% | -10.85% | 2.36% | 10.28% |
Profit Margin | -12.17% | -3.51% | -21.86% | -17.15% | 4.68% | 9.19% |
Free Cash Flow Margin | 12.79% | -108.38% | 39.40% | 177.23% | 59.15% | 24.10% |
EBITDA | -0.42 | 0.4 | 0.53 | -0.22 | 0.68 | 1.67 |
EBITDA Margin | -5.53% | 5.26% | 6.55% | -3.57% | 12.61% | 14.04% |
D&A For EBITDA | 0.29 | 0.29 | 0.29 | 0.45 | 0.55 | 0.45 |
EBIT | -0.71 | 0.11 | 0.24 | -0.67 | 0.13 | 1.22 |
EBIT Margin | -9.30% | 1.46% | 3.02% | -10.85% | 2.36% | 10.28% |
Effective Tax Rate | - | 434.18% | 52.74% | - | 207.38% | 19.91% |
Revenue as Reported | 0.12 | - | - | - | - | - |